Who are Fenretinide Lym-X-Sorb Oral Powder's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sohonos, Targretin, Panretin, Differin, Tegison, Accutane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fenretinide-lym-x-sorb-oral-powder.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Fenretinide Lym-X-Sorb Oral Powder — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fenretinide Lym-X-Sorb Oral Powder (Fenretinide Lym-X-Sorb Oral Powder) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: retinoid. Area: Oncology.

phase 2 retinoid retinoic acid receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fenretinide Lym-X-Sorb Oral Powder (Fenretinide Lym-X-Sorb Oral Powder) — South Plains Oncology Consortium. Fenretinide is a synthetic retinoid that induces apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fenretinide Lym-X-Sorb Oral Powder TARGET	Fenretinide Lym-X-Sorb Oral Powder	South Plains Oncology Consortium	phase 2	retinoid	retinoic acid receptor
Sohonos	PALOVAROTENE	Ipsen	marketed	Retinoid [EPC]	Retinoic acid receptor gamma	2023-01-01
Targretin	BEXAROTENE	Bausch Health	marketed	Retinoid [EPC]	Retinoic acid receptor RXR-beta	1999-01-01
Panretin	ALITRETINOIN	Advanz	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1999-01-01
Differin	ADAPALENE	Galderma Labs Lp	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1996-01-01
Tegison	ETRETINATE		marketed	Retinoid	Retinoic acid receptor RXR-gamma	1986-01-01
Accutane	ISOTRETINOIN		marketed	Retinoid [EPC]	Retinoic acid receptor alpha	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-09-15 — Differin · 8435502 · Formulation · US
2026-09-15 — Differin · 8709392 · Formulation · US
2028-05-31 — Differin · 7998467 · Formulation · US
2035-05-29 — Accutane · 9750711 · Formulation · US
2035-08-04 — Accutane · 9700535 · Formulation · US

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fenretinide Lym-X-Sorb Oral Powder — Competitive Intelligence Brief. https://druglandscape.com/ci/fenretinide-lym-x-sorb-oral-powder. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab